Postmenopausal Vaginal Atrophy Drugs Market by Type and Application - Global Industry Analysis & Forecast to 2027
Published On : October 2019 Pages : 150 Category: Pharma & Healthcare Report Code : HC106569
Postmenopausal Vaginal Atrophy Drugs Market by Type (Estrogen-Based Drugs, Non-Estrogen-Based Drugs) Application (Creams, Rings, Vaginal Gels, Tablets, Patches) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Postmenopausal Vaginal Atrophy Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Postmenopausal vaginal decay (PVA) refers to decrease in estrogen generation after menopause and this condition is likewise called as vaginal atrophy. Less estrogen prompts diminishing, drying, and diminished versatility of vaginal tissues. Different aspect that leads to diminish in estrogen levels incorporate perimenopause during bosom sustaining, pelvic radiation treatment, careful menopause and chemotherapy.
Drivers and Restraints
Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
Regional Insights
The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Bionovo, Inc.
- Allergan plc
- Actavis plc
- Shionogi & Company
- Endoceutics, Inc.
- Novo Nordisk A/S
- Teva Pharmaceuticals Ltd.
- Pfizer Inc.
- Therapeutics MD, Inc.
- Shionogi & Co. Ltd.
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Postmenopausal Vaginal Atrophy Drugs Market , By Type, Estimates and Forecast, 2017-2027 ($Million)
o Estrogen-Based Drugs
o Non-Estrogen-Based Drugs
· Postmenopausal Vaginal Atrophy Drugs Market , By Application, Estimates and Forecast, 2017-2027 ($Million)
o Creams
o Rings
o Vaginal Gels
o Tablets
o Patches
· Postmenopausal Vaginal Atrophy Drugs Market , By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Bionovo, Inc.
o Allergan plc
o Actavis plc
o Shionogi & Company
o Endoceutics, Inc.
o Novo Nordisk A/S
o Teva Pharmaceuticals Ltd.
o Pfizer Inc.
o Therapeutics MD, Inc.
o Shionogi & Co. Ltd.
· Postmenopausal Vaginal Atrophy Drugs Market , By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Postmenopausal Vaginal Atrophy Drugs Market , By Country
o U.S. Postmenopausal Vaginal Atrophy Drugs Market
o Canada Postmenopausal Vaginal Atrophy Drugs Market
o Mexico Postmenopausal Vaginal Atrophy Drugs Market
o Europe
§ Europe Postmenopausal Vaginal Atrophy Drugs Market , By Country
· Germany Postmenopausal Vaginal Atrophy Drugs Market
o UK Postmenopausal Vaginal Atrophy Drugs Market
o France Postmenopausal Vaginal Atrophy Drugs Market
o Russia Postmenopausal Vaginal Atrophy Drugs Market
o Italy Postmenopausal Vaginal Atrophy Drugs Market
o Rest of Europe Postmenopausal Vaginal Atrophy Drugs Market
o Asia-Pacific
§ Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market , By Country
o China Postmenopausal Vaginal Atrophy Drugs Market
o Japan Postmenopausal Vaginal Atrophy Drugs Market
o South Korea Postmenopausal Vaginal Atrophy Drugs Market
o India Postmenopausal Vaginal Atrophy Drugs Market
o Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market
o Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market
o South America
§ South America Postmenopausal Vaginal Atrophy Drugs Market
o Brazil Postmenopausal Vaginal Atrophy Drugs Market
o Argentina Postmenopausal Vaginal Atrophy Drugs Market
o Columbia Postmenopausal Vaginal Atrophy Drugs Market
o Rest of South America Postmenopausal Vaginal Atrophy Drugs Market
o Middle East and Africa
§ Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market
o Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market
o UAE Postmenopausal Vaginal Atrophy Drugs Market
o Egypt Postmenopausal Vaginal Atrophy Drugs Market
o Nigeria Postmenopausal Vaginal Atrophy Drugs Market
o South Africa Postmenopausal Vaginal Atrophy Drugs Market
o Rest of MEA Postmenopausal Vaginal Atrophy Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Postmenopausal Vaginal Atrophy Drugs Market, By Type
5.1. Introduction
5.2. Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Type (2017-2027)
5.2.1. Global Postmenopausal Vaginal Atrophy Drugs Revenue and Revenue Share by Type (2017-2027)
5.3. Estrogen-Based Drugs
5.3.1. Global Estrogen-Based Drugs Revenue and Growth Rate (2017-2027)
5.4. Non-Estrogen-Based Drugs
5.4.1. Global Non-Estrogen-Based Drugs Revenue and Growth Rate (2017-2027)
6. Postmenopausal Vaginal Atrophy Drugs Market, By Application
6.1. Introduction
6.2. Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Application (2017-2027)
6.2.1. Global Postmenopausal Vaginal Atrophy Drugs Revenue and Revenue Share by Application (2017-2027)
6.3. Creams
6.3.1. Global Creams Revenue and Growth Rate (2017-2027)
6.4. Rings
6.4.1. Global Rings Revenue and Growth Rate (2017-2027)
6.5. Vaginal Gels
6.5.1. Global Vaginal Gels Revenue and Growth Rate (2017-2027)
6.6. Tablets
6.6.1. Global Tablets Revenue and Growth Rate (2017-2027)
6.7. Patches
6.7.1. Global Patches Revenue and Growth Rate (2017-2027)
7. Postmenopausal Vaginal Atrophy Drugs Market, By Region
7.1. Introduction
7.2. Global Postmenopausal Vaginal Atrophy Drugs Revenue and Market Share by Regions
7.2.1. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions (2017-2027)
7.3. North America Postmenopausal Vaginal Atrophy Drugs by Countries
7.3.1. North America Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2027)
7.3.2. North America Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Postmenopausal Vaginal Atrophy Drugs by Countries
7.4.1. Europe Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2027)
7.4.2. Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs by Countries
7.5.1. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Postmenopausal Vaginal Atrophy Drugs by Countries
7.6.1. South America Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2027)
7.6.2. South America Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Countries
7.7.1. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Bionovo, Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Allergan plc
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Actavis plc
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Shionogi & Company
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Endoceutics, Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. Novo Nordisk A/S
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Teva Pharmaceuticals Ltd.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Pfizer Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Therapeutics MD, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Shionogi & Co. Ltd.
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.1. Global Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Postmenopausal Vaginal Atrophy Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.1.1. United States Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2. Europe Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.2. France Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.3. UK Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.1. China Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.4. India Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.4. South America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2017-2027)
9.3. Postmenopausal Vaginal Atrophy Drugs Market Forecast by Type (2017-2027)
9.3.1. Postmenopausal Vaginal Atrophy Drugs Forecast by Type (2017-2027)
9.3.2. Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Type (2017-2027)
9.4. Postmenopausal Vaginal Atrophy Drugs Market Forecast by Application (2017-2027)
9.4.1. Postmenopausal Vaginal Atrophy Drugs Forecast by Application (2017-2027)
9.4.2. Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue and Revenue Share by Type (2017-2018)
Figure Global Estrogen-Based Drugs Revenue and Growth Rate (2017-2018)
Figure Global Non-Estrogen-Based Drugs Revenue and Growth Rate (2017-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue and Revenue Share by Application (2017-2018)
Figure Global Creams Revenue and Growth Rate (2017-2018)
Figure Global Rings Revenue and Growth Rate (2017-2018)
Figure Global Vaginal Gels Revenue and Growth Rate (2017-2018)
Figure Global Tablets Revenue and Growth Rate (2017-2018)
Figure Global Patches Revenue and Growth Rate (2017-2018)
Table Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions (2017-2018)
Figure North America Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure North America Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2018)
Figure North America Postmenopausal Vaginal Atrophy Drugs by Countries (2017-2018)
Figure North America Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure United States Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs by Countries (2017-2018)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure France Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure UK Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Rest of Europe Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Postmenopausal Vaginal Atrophy Drugs by Countries (2017-2018)
Figure Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure China Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure India Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure South America Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2018)
Figure South America Postmenopausal Vaginal Atrophy Drugs by Countries (2017-2018)
Figure South America Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Columbia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Rest of South America Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Countries (2017-2018)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Allergan plc Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Actavis plc Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Table Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Financial Overview
Figure Global Postmenopausal Vaginal Atrophy Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Postmenopausal Vaginal Atrophy Drugs Market Forecast by Regions (2018-2025)
Figure North America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure United States Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Canada Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Mexico Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Europe Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Germany Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure France Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure UK Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Russia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Italy Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Rest of Europe Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure China Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Japan Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Korea Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure India Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Southeast Asia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure South America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Brazil Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Argentina Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Columbia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Rest of South America Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Egypt Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Nigeria Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure South Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Turkey Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Forecast (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Forecast by Type (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Type (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Forecast by Type (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Forecast by Application (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Application (2018-2025)
Figure Global Postmenopausal Vaginal Atrophy Drugs Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|